Neuroimaging Biomarkers for Drug Discovery and Development in Schizophrenia
Preller K, Scholpp J, Wunder A, Rosenbrock H. Neuroimaging Biomarkers for Drug Discovery and Development in Schizophrenia. Biological Psychiatry 2024, 96: 666-673. PMID: 38272287, DOI: 10.1016/j.biopsych.2024.01.009.Peer-Reviewed Original ResearchNMDA receptor hypofunctionPsychosis spectrum disordersNeuroimaging data acquisitionField of neuroimagingNegative symptomsPharmacological neuroimagingPositive symptomsReceptor hypofunctionPsychotic disordersNeuroimaging resultsSpectrum disorderNeuroimaging technologiesNeuroimaging biomarkersSchizophreniaNeuroimagingPathophysiology of symptomsDrug developmentDecades of researchTarget engagementClinical drug developmentPredictive biomarkersDisordersSymptomsHealthy volunteersDose selectionKnowledge gaps in psychedelic medicalisation: Preclinical and neuroimaging mechanisms
McCulloch D, Lopez J, Dalla C, Castrén E, Erritzoe D, Frokjaer V, Lundberg J, Preller K, Fisher P, Knudsen G. Knowledge gaps in psychedelic medicalisation: Preclinical and neuroimaging mechanisms. Neuroscience Applied 2024, 3: 103929. DOI: 10.1016/j.nsa.2023.103929.Peer-Reviewed Original ResearchSerotonin 2A receptorFunctional brain activityMechanism of actionClinical effectsPreclinical modelsBrain disordersClinical neuroimagingDose optimizationNeurotransmitter releaseEffects of psychedelicsBrain activitySex differencesPsychedelic drugsMolecular mechanismsKnowledge gapsPsychedelicsAppropriate behavioral modelsPreclinicalNeuroimagingReceptors